Cargando…

Use of health technology assessment in drug reimbursement decisions in China

China has made substantial progress in using health technology assessment, but more effort should be made to improve the quality of evidence, strengthen capacity, and enhance transparency, say Wen Chen and colleagues

Detalles Bibliográficos
Autores principales:	Chen, Wen, Zhang, Luying, Hu, Min, Hu, Shanlian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group Ltd. 2023
Materias:	Analysis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266437/ https://www.ncbi.nlm.nih.gov/pubmed/37321619 http://dx.doi.org/10.1136/bmj-2021-068915

Ejemplares similares

Using health technology assessment to inform insurance reimbursement of high technology medicines in China: an example of cancer immunotherapy
por: Chen, Yingyao, et al.
Publicado: (2023)

Use of health technology assessment in drug reimbursement decisions in China
Publicado: (2023)

How health technology reassessment can support disinvestment in China’s national drug reimbursement list
por: Shi, Lizheng, et al.
Publicado: (2023)

Health technology assessment to inform decision making in China: progress, challenges, and sustainability
por: Chen, Yingyao, et al.
Publicado: (2023)

Drug pricing and reimbursement decision making systems in Mongolia
por: Dorj, Gereltuya, et al.
Publicado: (2017)

Using economic evaluations to support acupuncture reimbursement decisions: current evidence and gaps
por: Li, Hongchao, et al.
Publicado: (2022)

Use of real world data to improve drug coverage decisions in China
por: Wang, Wen, et al.
Publicado: (2023)

Conflict of interest in Health Technology Assessment decisions: case law in France and impact on reimbursement decisions
por: Frybourg, Sandrine, et al.
Publicado: (2015)

Description of the use of multicriteria to support pricing and reimbursement decisions by European health technology assessment bodies
por: Elvira, David, et al.
Publicado: (2021)

Institutionalising health technology assessment: establishing the Medical Technology Assessment Board in India
por: Downey, Laura E, et al.
Publicado: (2017)

The reimbursement decision speed for oncology new drugs in China and its determinant factors
por: Zhu, Xingyue, et al.
Publicado: (2023)

Reimbursement of Orphan Drugs in Europe in Relation to the Type of Authorization by the European Medicines Agency and the Decision Making Based on Health Technology Assessment
por: Malinowski, Krzysztof Piotr, et al.
Publicado: (2018)

Using multicriteria decision analysis during drug development to predict reimbursement decisions
por: Williams, Paul, et al.
Publicado: (2014)

Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe
por: Malinowski, Krzysztof Piotr, et al.
Publicado: (2020)

Pre-reimbursement: early assessment for coverage decisions
por: Grössmann, Nicole, et al.
Publicado: (2019)

Reimbursement of pharmaceuticals: reference pricing versus health technology assessment
por: Drummond, Michael, et al.
Publicado: (2010)

Assessment of the clinical and cost-effectiveness evidence in the reimbursement decisions of new cancer drugs
por: Chauca Strand, G., et al.
Publicado: (2022)

Correlation between clinical trial endpoints of marketed cancer drugs and reimbursement decisions in China
por: Ling, Kexin, et al.
Publicado: (2022)

Role of centralized review processes for making reimbursement decisions on new health technologies in Europe
por: Stafinski, Tania, et al.
Publicado: (2011)

Reporting reimbursement price decisions for onco-hematology drugs in Spain
por: Elvira, David, et al.
Publicado: (2023)

Weighing of Evidence by Health Technology Assessment Bodies: Retrospective Study of Reimbursement Recommendations for Conditionally Approved Drugs
por: Vreman, Rick A., et al.
Publicado: (2018)

Health Technology Assessment Process for Oncology Drugs: Impact of CADTH Changes on Public Payer Reimbursement Recommendations
por: Binder, Louise, et al.
Publicado: (2022)

Access to innovative drugs and the National Reimbursement Drug List in China: Changing dynamics and future trends in pricing and reimbursement
por: Macabeo, Bérengère, et al.
Publicado: (2023)

Use of Patient Preference Information in Benefit–Risk Assessment, Health Technology Assessment, and Pricing and Reimbursement Decisions: A Systematic Literature Review of Attempts and Initiatives
por: Chachoua, Lylia, et al.
Publicado: (2020)

The Potential for Early Health Economic Modelling in Health Technology Assessment and Reimbursement Decision-Making Comment on "Problems and Promises of Health Technologies: The Role of Early Health Economic Modeling"
por: Kim, Hansoo, et al.
Publicado: (2020)

Rational use of antibiotics in the context of China’s health system reform
por: He, Ping, et al.
Publicado: (2019)

Value-Based Reimbursement Decisions for Orphan Drugs: A Scoping Review and Decision Framework
por: Paulden, Mike, et al.
Publicado: (2014)

Research in health policy making in China: out-of-pocket payments in Healthy China 2030
por: Fu, Wei, et al.
Publicado: (2018)

Is Canada missing out? An assessment of drugs approved internationally between 2016 and 2020 and not submitted for Health Canada review
por: Gaudette, Étienne, et al.
Publicado: (2023)

Decision aids that really promote shared decision making: the pace quickens
por: Agoritsas, Thomas, et al.
Publicado: (2015)

Do Health Technology Assessment organisations consider manufacturers’ costs in relation to drug price? A study of reimbursement reports
por: Enzing, Joost J., et al.
Publicado: (2022)

Decision-making processes for essential packages of health services: experience from six countries
por: Baltussen, Rob, et al.
Publicado: (2023)

Disagreement among experts about public health decision making: is it polarisation and does it matter?
por: Williams, Jane H, et al.
Publicado: (2023)

Implications of a complexity perspective for systematic reviews and guideline development in health decision making
por: Petticrew, Mark, et al.
Publicado: (2019)

Collective sensemaking for action: researchers and decision makers working collaboratively to strengthen health systems
por: Gilson, Lucy, et al.
Publicado: (2021)

From blockchain technology to global health equity: can cryptocurrencies finance universal health coverage?
por: Till, Brian M, et al.
Publicado: (2017)

Strengthening public health services to achieve universal health coverage in China
por: Yuan, Beibei, et al.
Publicado: (2019)

Reimbursement Legislations and Decision Making for Orphan Drugs in Central and Eastern European Countries
por: Malinowski, Krzysztof Piotr, et al.
Publicado: (2019)

Drug pricing and reimbursement information management: processes and decision making in the global economy
por: Tsourougiannis, Dimitrios
Publicado: (2017)

Towards universal health coverage: achievements and challenges of 10 years of healthcare reform in China
por: Tao, Wenjuan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jb71met20e6kv6gba3p4cjassr